WO2009028605A1 - 抗がん剤による末梢神経障害の予防又は軽減剤 - Google Patents

抗がん剤による末梢神経障害の予防又は軽減剤 Download PDF

Info

Publication number
WO2009028605A1
WO2009028605A1 PCT/JP2008/065399 JP2008065399W WO2009028605A1 WO 2009028605 A1 WO2009028605 A1 WO 2009028605A1 JP 2008065399 W JP2008065399 W JP 2008065399W WO 2009028605 A1 WO2009028605 A1 WO 2009028605A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
peripheral nerve
prophylactic
nerve disorder
alleviating
Prior art date
Application number
PCT/JP2008/065399
Other languages
English (en)
French (fr)
Inventor
Ryozo Oishi
Yoshinori Itoh
Nobuaki Egashira
Original Assignee
Kyushu University, National University Corporation
Nippon Zoki Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation, Nippon Zoki Pharmaceutical Co., Ltd. filed Critical Kyushu University, National University Corporation
Priority to AU2008292407A priority Critical patent/AU2008292407B2/en
Priority to JP2009530176A priority patent/JPWO2009028605A1/ja
Priority to US12/674,972 priority patent/US8613962B2/en
Priority to CA2698129A priority patent/CA2698129A1/en
Priority to EP08828811A priority patent/EP2191836B1/en
Priority to ES08828811T priority patent/ES2385069T3/es
Priority to CN200880104315A priority patent/CN101790377A/zh
Publication of WO2009028605A1 publication Critical patent/WO2009028605A1/ja
Priority to HK10110083.5A priority patent/HK1143734A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

本発明の目的は、抗がん剤投与時の副作用として発現する末梢神経障害の予防又は軽減において、有効で且つ安全性が高い薬剤を提供することにある。本発明はワクシニアウイルス接種炎症組織抽出物の新規な医薬用途に関するものであり、該抽出物を有効成分として含有する末梢神経障害の予防又は軽減剤に関する。該抽出物を有効成分とする本発明薬剤は、抗がん剤の投与によって引き起こされる末梢神経障害の予防又は軽減剤として、副作用の少ない安全性の高い薬剤として有用性の高いものである。
PCT/JP2008/065399 2007-08-31 2008-08-28 抗がん剤による末梢神経障害の予防又は軽減剤 WO2009028605A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2008292407A AU2008292407B2 (en) 2007-08-31 2008-08-28 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
JP2009530176A JPWO2009028605A1 (ja) 2007-08-31 2008-08-28 抗がん剤による末梢神経障害の予防又は軽減剤
US12/674,972 US8613962B2 (en) 2007-08-31 2008-08-28 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
CA2698129A CA2698129A1 (en) 2007-08-31 2008-08-28 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
EP08828811A EP2191836B1 (en) 2007-08-31 2008-08-28 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
ES08828811T ES2385069T3 (es) 2007-08-31 2008-08-28 Agentes profilácticos o de alivio para trastorno nervioso periférico inducido por agente anti-cáncer
CN200880104315A CN101790377A (zh) 2007-08-31 2008-08-28 抗癌剂导致的末梢神经障碍的预防或减轻剂
HK10110083.5A HK1143734A1 (en) 2007-08-31 2010-10-27 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007225420 2007-08-31
JP2007-225420 2007-08-31
JP2008032626 2008-02-14
JP2008-032626 2008-02-14

Publications (1)

Publication Number Publication Date
WO2009028605A1 true WO2009028605A1 (ja) 2009-03-05

Family

ID=40387319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065399 WO2009028605A1 (ja) 2007-08-31 2008-08-28 抗がん剤による末梢神経障害の予防又は軽減剤

Country Status (11)

Country Link
US (1) US8613962B2 (ja)
EP (1) EP2191836B1 (ja)
JP (1) JPWO2009028605A1 (ja)
KR (1) KR20100057535A (ja)
CN (1) CN101790377A (ja)
AU (1) AU2008292407B2 (ja)
CA (1) CA2698129A1 (ja)
ES (1) ES2385069T3 (ja)
HK (1) HK1143734A1 (ja)
TW (1) TW200911277A (ja)
WO (1) WO2009028605A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107710A1 (fr) * 2010-03-02 2011-09-09 Universite D'auvergne Clermont I Utilisation du riluzole pour traiter ou prévenir les effets indésirables d'agents anti-cancéreux
WO2011111770A1 (ja) 2010-03-11 2011-09-15 日本臓器製薬株式会社 慢性前立腺炎、間質性膀胱炎及び／又は排尿障害の改善又は治療剤
WO2011162317A1 (ja) 2010-06-25 2011-12-29 日本臓器製薬株式会社 被検物質の判定又は評価方法
WO2012105476A1 (ja) * 2011-01-31 2012-08-09 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
KR101732483B1 (ko) 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
US10711292B2 (en) 2010-10-14 2020-07-14 Nikkon Zoki Pharmaceutical Co., Ltd. Method for promoting the synthesis of collagen and proteoglycan in chondrocytes

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5275502B1 (ja) * 2012-10-10 2013-08-28 日本臓器製薬株式会社 抽出物及び製剤
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
WO2020067389A1 (ja) * 2018-09-28 2020-04-02 旭化成ファーマ株式会社 抗悪性腫瘍剤による末梢神経障害の症状軽減及び／又は発症抑制のための医薬

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53101515A (en) 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS5587724A (en) 1978-12-27 1980-07-02 Nippon Zoki Pharmaceut Co Ltd Selective immune enhancer
JPH01265028A (ja) 1988-04-15 1989-10-23 Nippon Zoki Pharmaceut Co Ltd 特発性血小板減少性紫斑病治療剤
JPH01319422A (ja) 1988-06-20 1989-12-25 Nippon Zoki Pharmaceut Co Ltd 神経疾患治療剤
JPH0228119A (ja) 1988-07-15 1990-01-30 Nippon Zoki Pharmaceut Co Ltd 糖尿病性神経障害治療剤
JPH0797336A (ja) 1993-09-28 1995-04-11 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質−ｋｆ
JPH08291077A (ja) 1995-04-25 1996-11-05 Nippon Zoki Pharmaceut Co Ltd 骨萎縮改善剤
JPH10194978A (ja) 1997-01-08 1998-07-28 Nippon Zoki Pharmaceut Co Ltd 一酸化窒素産生抑制剤
JPH1180005A (ja) 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
JPH11139977A (ja) 1997-11-07 1999-05-25 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ作用抑制剤
JP2000016942A (ja) 1998-04-27 2000-01-18 Nippon Zoki Pharmaceut Co Ltd 虚血性疾患治療剤
JP2000336034A (ja) 1999-03-19 2000-12-05 Nippon Zoki Pharmaceut Co Ltd ケモカイン産生促進剤
WO2004039383A1 (ja) 2002-10-31 2004-05-13 Nippon Zoki Pharmaceutical Co., Ltd. 線維筋痛症治療剤
JP2004300146A (ja) 2003-03-17 2004-10-28 Nippon Zoki Pharmaceut Co Ltd 感染防御剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2922828B2 (ja) * 1995-08-10 1999-07-26 朝日電装株式会社 イグニッションスイッチ
US20030199535A1 (en) 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
EP1100589B1 (en) 1998-07-30 2005-01-19 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity
US8071492B2 (en) * 2001-08-20 2011-12-06 Pbi Performance Products, Inc. Textile fabric for the outer shell of a firefighter's garment
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53101515A (en) 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS5587724A (en) 1978-12-27 1980-07-02 Nippon Zoki Pharmaceut Co Ltd Selective immune enhancer
JPH01265028A (ja) 1988-04-15 1989-10-23 Nippon Zoki Pharmaceut Co Ltd 特発性血小板減少性紫斑病治療剤
JPH01319422A (ja) 1988-06-20 1989-12-25 Nippon Zoki Pharmaceut Co Ltd 神経疾患治療剤
JPH0228119A (ja) 1988-07-15 1990-01-30 Nippon Zoki Pharmaceut Co Ltd 糖尿病性神経障害治療剤
JPH0797336A (ja) 1993-09-28 1995-04-11 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質−ｋｆ
JPH08291077A (ja) 1995-04-25 1996-11-05 Nippon Zoki Pharmaceut Co Ltd 骨萎縮改善剤
JPH10194978A (ja) 1997-01-08 1998-07-28 Nippon Zoki Pharmaceut Co Ltd 一酸化窒素産生抑制剤
JPH1180005A (ja) 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
JPH11139977A (ja) 1997-11-07 1999-05-25 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ作用抑制剤
JP2000016942A (ja) 1998-04-27 2000-01-18 Nippon Zoki Pharmaceut Co Ltd 虚血性疾患治療剤
JP2000336034A (ja) 1999-03-19 2000-12-05 Nippon Zoki Pharmaceut Co Ltd ケモカイン産生促進剤
WO2004039383A1 (ja) 2002-10-31 2004-05-13 Nippon Zoki Pharmaceutical Co., Ltd. 線維筋痛症治療剤
JP2004300146A (ja) 2003-03-17 2004-10-28 Nippon Zoki Pharmaceut Co Ltd 感染防御剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Drugs in Japan, Ethical Drugs", 2007, JAPAN PHARMACEUTICAL INFORMATION CENTER, pages: 2697 - 2699
See also references of EP2191836A4

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511045B2 (en) 2010-03-02 2016-12-06 Universite D'auvergne Clermont I Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
WO2011107710A1 (fr) * 2010-03-02 2011-09-09 Universite D'auvergne Clermont I Utilisation du riluzole pour traiter ou prévenir les effets indésirables d'agents anti-cancéreux
WO2011111770A1 (ja) 2010-03-11 2011-09-15 日本臓器製薬株式会社 慢性前立腺炎、間質性膀胱炎及び／又は排尿障害の改善又は治療剤
US9011849B2 (en) 2010-03-11 2015-04-21 Nippon Zoki Pharmaceutical Co., Ltd. Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders
WO2011162317A1 (ja) 2010-06-25 2011-12-29 日本臓器製薬株式会社 被検物質の判定又は評価方法
US9447466B2 (en) 2010-06-25 2016-09-20 Nippon Zoki Pharmaceutical Co., Ltd. Method for determination or evaluation of test substance
US10711292B2 (en) 2010-10-14 2020-07-14 Nikkon Zoki Pharmaceutical Co., Ltd. Method for promoting the synthesis of collagen and proteoglycan in chondrocytes
WO2012105476A1 (ja) * 2011-01-31 2012-08-09 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
JP5009451B1 (ja) * 2011-01-31 2012-08-22 日本臓器製薬株式会社 抗がん剤による末梢神経障害の予防又は治療剤
US9884077B2 (en) 2013-04-30 2018-02-06 Nippon Zoki Pharmaceutical Co., Ltd. Extract and preparation containing said extract
KR101732483B1 (ko) 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
WO2018056412A1 (ja) * 2016-09-23 2018-03-29 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
US11207354B2 (en) 2016-09-23 2021-12-28 Osaka University Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent

Also Published As

Publication number Publication date
US20110111051A1 (en) 2011-05-12
JPWO2009028605A1 (ja) 2010-12-02
EP2191836A1 (en) 2010-06-02
CN101790377A (zh) 2010-07-28
HK1143734A1 (en) 2011-01-14
CA2698129A1 (en) 2009-03-05
AU2008292407B2 (en) 2013-12-12
EP2191836B1 (en) 2012-05-23
AU2008292407A1 (en) 2009-03-05
ES2385069T3 (es) 2012-07-17
US8613962B2 (en) 2013-12-24
TW200911277A (en) 2009-03-16
EP2191836A4 (en) 2011-03-30
KR20100057535A (ko) 2010-05-31

Similar Documents

Publication Publication Date Title
WO2009028605A1 (ja) 抗がん剤による末梢神経障害の予防又は軽減剤
WO2010128087A3 (en) Uses of immunoconjugates targeting cd138
WO2010109482A3 (en) Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
WO2013063120A3 (en) Nmda receptor modulators and uses thereof
WO2008154368A3 (en) Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
UA99150C2 (ru) Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
RS54438B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE
WO2012087047A3 (en) Percutaneous absorption preparation containing rivastigmine
WO2011041632A3 (en) Combination therapies for the treatment of obesity
WO2011063178A3 (en) Intravenous infusion of curcumin and a calcium channel blocker
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
WO2010151503A3 (en) Combination therapies for the treatment of obesity
WO2011129765A9 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
WO2011044523A3 (en) Compositions and methods for treating obesity
MX362830B (es) Agente terapeutico o profilactico para enfermedades del tracto biliar.
EP2545929A4 (en) ENHANCING OR TREATING AGENT FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND / OR MICTION DISORDERS
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
WO2010045522A3 (en) Combination therapies for the treatment of obesity
WO2016108572A3 (ko) 콜레스테롤 관련 질환의 예방 및 치료용 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880104315.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828811

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009530176

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20097026816

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008292407

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2698129

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008828811

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008292407

Country of ref document: AU

Date of ref document: 20080828

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12674972

Country of ref document: US